Midazolam Accord (Midazolam)

Midazolam enhances the activity of the neurotransmitter GABA at the GABAA receptor complex. By binding to a specific benzodiazepine site, it increases the frequency of chloride channel opening, leading to neuronal hyperpolarization and reduced excitability. This mechanism produces sedation, anxiolysis, muscle relaxation, and anticonvulsant effects.

The dosage of Midazolam Accord is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, route of administration and desired depth of sedation. Healthcare providers calculate the appropriate amount and adjust it as needed during treatment, following local guidelines and institutional protocols.

Midazolam is classified as a pregnancy category that requires careful risk‑benefit assessment. It can cross the placenta and may affect the fetus, and it is excreted in breast milk. Use during pregnancy or lactation should only occur when clearly indicated and under close medical supervision.

To order Midazolam Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Midazolam is a short‑acting benzodiazepine, offering rapid onset and relatively predictable recovery compared with longer‑acting agents such as diazepam. Compared with propofol, it provides less profound hypnosis but has strong anxiolytic and anticonvulsant properties, making it suitable for procedural sedation and seizure control where a brief, controllable effect is desired.

Midazolam Accord should be stored at controlled room temperature, below 25 °C, in its original packaging to protect it from moisture and light. The product must be kept in a secure area with limited access, and any unused portion should be discarded according to local regulations after the expiry date.

Midazolam can be given by intramuscular, intravenous or rectal routes, depending on the clinical situation. Intravenous injection provides the fastest onset, while intramuscular injection is useful when IV access is not available. Rectal administration is an alternative for emergency seizure control, especially in pediatric patients.

The most serious risks include respiratory depression, severe hypotension, paradoxical reactions such as agitation, and rare allergic responses. Continuous monitoring of breathing, blood pressure and level of consciousness is essential, especially when higher doses are used or when the drug is combined with other central nervous system depressants.

Midazolam is contraindicated in patients with known hypersensitivity to benzodiazepines, severe respiratory depression, acute narrow‑angle glaucoma, and in individuals who are currently intoxicated with alcohol or other CNS depressants. Caution is also advised for patients with significant hepatic impairment or a history of substance dependence.